Insider · CIK 0001817217

van Houte Hans

Reports to the SEC for 1 company · BRISBANE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001817217

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-04	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,794 sh	$23.89	−$42.9K	43,133
2026-08-04	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,967 sh	$24.65	−$73.1K	40,166
2026-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,750 sh	—	—	41,342
2026-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,858 sh	—	—	44,200
2026-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,572 sh	—	—	47,772
2026-07-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,845 sh	$23.38	−$66.5K	44,927
2026-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,750 sh	—	—	11,250
2026-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,858 sh	—	—	20,009
2026-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,572 sh	—	—	39,303
2026-05-05	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−13.5K sh	$16.58	−$223K	38,174
2026-05-05	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−582 sh	$17.18	−$9,995.908	37,592
2026-04-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	47,427
2026-04-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,750 sh	—	—	51,177
2026-04-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,858 sh	—	—	54,035
2026-04-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,388 sh	$16.65	−$39.7K	51,647
2026-04-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	0
2026-04-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,750 sh	—	—	15,000
2026-04-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,858 sh	—	—	22,867
2026-02-10	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+93.8K sh	—	—	93,750
2026-02-10	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+42.9K sh	—	—	42,875
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,887 sh	—	—	40,479
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	42,479
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,750 sh	—	—	46,229
2026-01-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,859 sh	—	—	49,088
2026-01-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,588 sh	$16.58	−$59.5K	45,500
2026-01-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−73 sh	$17.37	−$1,268.134	45,427
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,887 sh	—	—	0
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	2,000
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,750 sh	—	—	18,750
2026-01-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,859 sh	—	—	25,725
2025-11-03	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,284 sh	$12.56	−$78.9K	37,592
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,886 sh	—	—	38,398
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	40,398
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,750 sh	—	—	44,148
2025-10-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,858 sh	—	—	47,006
2025-10-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,130 sh	$12.80	−$40.1K	43,876
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,886 sh	—	—	2,887
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	4,000
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,750 sh	—	—	22,500
2025-10-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,858 sh	—	—	28,584
2025-08-01	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,402 sh	$11.03	−$59.6K	35,512
2025-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,886 sh	—	—	36,610
2025-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	38,610
2025-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,750 sh	—	—	42,360
2025-07-30	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,858 sh	—	—	45,218
2025-07-30	NRIXNurix Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,304 sh	$12.01	−$51.7K	40,914
2025-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,886 sh	—	—	5,773
2025-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	6,000
2025-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,750 sh	—	—	26,250
2025-07-30	NRIXNurix Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,858 sh	—	—	31,442

Recent filings

Accepted (ET)
Aug 44
van Houte Hans0001817217-26-000012
SEC(opens sec.gov)
Jul 304
van Houte Hans0001817217-26-000010
SEC(opens sec.gov)
May 54
van Houte Hans0001817217-26-000008
SEC(opens sec.gov)
Apr 304
van Houte Hans0001817217-26-000006
SEC(opens sec.gov)
Feb 104
van Houte Hans0001817217-26-000004
SEC(opens sec.gov)

Companies

Nurix Therapeutics, Inc.Chief Financial OfficerNRIX

Address

C/O NURIX THERAPEUTICS, INC. 1600 SIERRA POINT PKWY

BRISBANE, CA, 94005